Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Clinical trial NCT02973399 · TERMINATED
Trial details
- NCT number
- NCT02973399
- Sponsor
- Esanex Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-07
- Primary completion
- 2018-12-04
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.